Comparative Efficacy and Safety of Traditional Chinese Patent Medicine for NAFLD in Childhood or Adolescence: A Protocol for a Bayesian Network Meta Analysis

Overview

Journal Medicine (Baltimore)

Specialty General Medicine

Date 2021 Feb 6

PMID 33546051

Citations 3

Authors

Yuli Sun

Zhaofeng Tan

Zhenyuan Jiang

Min Li

Weiqin Wang

Yaoyao Huang

Jianguang Sun

Affiliations

Soon will be listed here.

Abstract

Background: Nonalcoholic fatty liver disease is a common reason for chronic liver disease in children and adults. The increasing incidence of the disease has become one of the most critical public health problems in the 21st century, closely related to genetic and environmental factors. So far, apart from changing lifestyle and diet, modern medicine still lacks effective treatment measures. Chinese patent medicine has the advantages of apparent curative effect, overall regulation and fewer side effects. However, there is a lack of research on the simultaneous comparison of various Chinese patent medicines. Therefore, we used a reticular meta-analysis to indirectly compare the efficacy and safety of different oral Chinese patent medicines through standard reference.

Method: We will conduct a comprehensive and systematic search of Chinese and English databases from the beginning to December 2020. All randomized controlled trials (RCTs) of oral Chinese patent medicine for NAFLD in children will be searched. The 2 researchers then independently filter the retrieved literature, extract the data according to the data extraction table and assess the risk of bias. We will perform a pair of meta-analyses and a Bayesian network meta-analysis. STATA and Win BUGS software will be used for data analysis.

Results: This study will thoroughly compare and analyze the differences in the efficacy of all kinds of TCPM in NAFLD treatment in childhood or adolescence.

Conclusion: This study will provide reference and evidence support for clinical drug selection optimization.

Ethics And Dissemination: This study does not require ethical approval.

Inplasy Registration Number: 2020120068.

Citing Articles

Bioinformatics based exploration of the anti-NAFLD mechanism of Wang's empirical formula via TLR4/NF-κB/COX2 pathway.

Chen S, Zhou C, Huang J, Qiao Y, Wang N, Huang Y Mol Med. 2024; 30(1):278.

PMID: 39730994 PMC: 11673956. DOI: 10.1186/s10020-024-01022-3.

Dietary and Nutritional Interventions in Nonalcoholic Fatty Liver Disease in Pediatrics.

Farias C, Cisternas C, Gana J, Alberti G, Echeverria F, Videla L Nutrients. 2023; 15(22).

PMID: 38004223 PMC: 10674812. DOI: 10.3390/nu15224829.

Integrated strategy of RNA-sequencing and network pharmacology for exploring the protective mechanism of Shen-Shi-Jiang-Zhuo formula in rat with non-alcoholic fatty liver disease.

Xu Z, Wu F, Niu X, Lu X, Li Y, Zhang S Pharm Biol. 2022; 60(1):1819-1838.

PMID: 36124995 PMC: 9518293. DOI: 10.1080/13880209.2022.2106250.

References

Hartmann P, Schnabl B . Risk factors for progression of and treatment options for NAFLD in children. Clin Liver Dis (Hoboken). 2018; 11(1):11-15. PMC: 5881937. DOI: 10.1002/cld.685. View

Dongiovanni P, Donati B, Fares R, Lombardi R, Mancina R, Romeo S . PNPLA3 I148M polymorphism and progressive liver disease. World J Gastroenterol. 2013; 19(41):6969-78. PMC: 3819533. DOI: 10.3748/wjg.v19.i41.6969. View

Chacko K, Reinus J . Extrahepatic Complications of Nonalcoholic Fatty Liver Disease. Clin Liver Dis. 2016; 20(2):387-401. DOI: 10.1016/j.cld.2015.10.004. View

Temple J, Cordero P, Li J, Nguyen V, Oben J . A Guide to Non-Alcoholic Fatty Liver Disease in Childhood and Adolescence. Int J Mol Sci. 2016; 17(6). PMC: 4926480. DOI: 10.3390/ijms17060947. View

Alexander J, Torbenson M, Wu T, Yeh M . Non-alcoholic fatty liver disease contributes to hepatocarcinogenesis in non-cirrhotic liver: a clinical and pathological study. J Gastroenterol Hepatol. 2013; 28(5):848-54. DOI: 10.1111/jgh.12116. View

Alisi A, Cianfarani S, Manco M, Agostoni C, Nobili V . Non-alcoholic fatty liver disease and metabolic syndrome in adolescents: pathogenetic role of genetic background and intrauterine environment. Ann Med. 2011; 44(1):29-40. DOI: 10.3109/07853890.2010.547869. View

Dongiovanni P, Romeo S, Valenti L . Genetic Factors in the Pathogenesis of Nonalcoholic Fatty Liver and Steatohepatitis. Biomed Res Int. 2015; 2015:460190. PMC: 4530215. DOI: 10.1155/2015/460190. View

Lawlor D, Callaway M, Macdonald-Wallis C, Anderson E, Fraser A, Howe L . Nonalcoholic fatty liver disease, liver fibrosis, and cardiometabolic risk factors in adolescence: a cross-sectional study of 1874 general population adolescents. J Clin Endocrinol Metab. 2014; 99(3):E410-7. PMC: 3955251. DOI: 10.1210/jc.2013-3612. View

Ranucci G, Spagnuolo M, Iorio R . Obese children with fatty liver: Between reality and disease mongering. World J Gastroenterol. 2018; 23(47):8277-8282. PMC: 5743498. DOI: 10.3748/wjg.v23.i47.8277. View

10.

Perticone M, Cimellaro A, Maio R, Caroleo B, Sciacqua A, Sesti G . Additive Effect of Non-Alcoholic Fatty Liver Disease on Metabolic Syndrome-Related Endothelial Dysfunction in Hypertensive Patients. Int J Mol Sci. 2016; 17(4):456. PMC: 4848912. DOI: 10.3390/ijms17040456. View

11.

Welsh J, Karpen S, Vos M . Increasing prevalence of nonalcoholic fatty liver disease among United States adolescents, 1988-1994 to 2007-2010. J Pediatr. 2012; 162(3):496-500.e1. PMC: 3649872. DOI: 10.1016/j.jpeds.2012.08.043. View

12.

Selvakumar P, Nasser Kabbany M, Nobili V, Alkhouri N . Nonalcoholic Fatty Liver Disease in Children: Hepatic and Extrahepatic Complications. Pediatr Clin North Am. 2017; 64(3):659-675. DOI: 10.1016/j.pcl.2017.01.008. View

13.

Vos M, Abrams S, Barlow S, Caprio S, Daniels S, Kohli R . NASPGHAN Clinical Practice Guideline for the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease in Children: Recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology.... J Pediatr Gastroenterol Nutr. 2017; 64(2):319-334. PMC: 5413933. DOI: 10.1097/MPG.0000000000001482. View

14.

. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016; 64(6):1388-402. DOI: 10.1016/j.jhep.2015.11.004. View

15.

Nobili V, Alisi A, Valenti L, Miele L, Feldstein A, Alkhouri N . NAFLD in children: new genes, new diagnostic modalities and new drugs. Nat Rev Gastroenterol Hepatol. 2019; 16(9):517-530. DOI: 10.1038/s41575-019-0169-z. View

16.

Dongiovanni P, Petta S, Maglio C, Fracanzani A, Pipitone R, Mozzi E . Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. Hepatology. 2014; 61(2):506-14. DOI: 10.1002/hep.27490. View

17.

Mann J, Valenti L, Scorletti E, Byrne C, Nobili V . Nonalcoholic Fatty Liver Disease in Children. Semin Liver Dis. 2018; 38(1):1-13. DOI: 10.1055/s-0038-1627456. View

18.

Li J, Zou B, Yeo Y, Feng Y, Xie X, Lee D . Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2019; 4(5):389-398. DOI: 10.1016/S2468-1253(19)30039-1. View

19.

Lavine J, Schwimmer J, Van Natta M, Molleston J, Murray K, Rosenthal P . Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA. 2011; 305(16):1659-68. PMC: 3110082. DOI: 10.1001/jama.2011.520. View

20.

Inge T, Zeller M, Jenkins T, Helmrath M, Brandt M, Michalsky M . Perioperative outcomes of adolescents undergoing bariatric surgery: the Teen-Longitudinal Assessment of Bariatric Surgery (Teen-LABS) study. JAMA Pediatr. 2013; 168(1):47-53. PMC: 4060250. DOI: 10.1001/jamapediatrics.2013.4296. View